Advancing Medicine Knowledge & Information
The U.S. Food and Drug Administration has approved Bristol Myers Squibb’s Zenbexus (iberdomide) for adults with relapsed or refractory multiple myeloma, expanding treatment options for patients whose disease has returned or stopped responding to previous therapies. Zenbexus is approved for use in combination with daratumumab and hyaluronidase-fihj and dexamethasone. The medicine belongs to a newer […]
Continue Reading
Pharmaceutical companies are increasingly delaying applications for health-insurance reimbursement for new medicines in Switzerland, raising concerns about patient access to innovative treatments. A survey by Swiss pharmaceutical industry association Interpharma found that seven of 22 innovative medicines introduced between January 2025 and June 2026 were not submitted for inclusion on Switzerland’s mandatory health-insurance reimbursement list. […]
Continue Reading
Major pharmaceutical companies are significantly expanding their manufacturing and research presence in the United States, with companies including Pfizer, Eli Lilly, Johnson & Johnson, Roche, AstraZeneca and Novartis announcing investments that together approach $500 billion. The investments cover new manufacturing facilities, research and development centers, supply-chain infrastructure and expansions of existing sites. The moves come […]
Continue Reading
India’s pharmaceutical industry is expected to fall significantly short of its previously established sales target for 2030 as trade uncertainty and disruptions to international shipping weigh on the sector. The Pharmaceuticals Export Promotion Council of India now expects the country’s pharmaceutical industry to reach approximately $80 billion to $90 billion in sales by 2030. That […]
Continue Reading
Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for approximately $10 billion, expanding its business beyond its established focus on cystic fibrosis and into rare endocrine diseases. Under the agreement, Vertex will pay $85 per Crinetics share, representing a premium of approximately 102% to Crinetics’ share price before the deal was announced. The transaction is […]
Continue Reading